BRIEF published on 10/15/2025 at 19:05, 3 months 23 days ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
BRIEF published on 10/15/2025 at 19:05, 3 months 23 days ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
PRESS RELEASE published on 10/15/2025 at 19:00, 3 months 23 days ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 3 months 23 days ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 3 months 29 days ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
BRIEF published on 10/09/2025 at 16:02, 3 months 29 days ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
PRESS RELEASE published on 10/09/2025 at 15:57, 3 months 29 days ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 4 months 7 days ago OSE Immunotherapeutics: Reorganization of the Board of Directors Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
BRIEF published on 09/30/2025 at 19:35, 4 months 7 days ago OSE Immunotherapeutics : Réorganisation du Conseil d'administration Biotechnologie Conseil D'administration Immunothérapie OSE Immunotherapeutics Markus Cappel
PRESS RELEASE published on 09/30/2025 at 19:30, 4 months 7 days ago Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors OSE Immunotherapeutics renews Board of Directors and elects Dr. Markus Cappel as Chairman. Shareholders vote on key appointments Board Of Directors Shareholders General Meeting OSE Immunotherapeutics Dr. Markus Cappel
Published on 02/07/2026 at 01:00, 1 day 6 hours ago Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 8 hours ago Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 9 hours ago Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 16 hours ago Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 18 hours ago Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange
Published on 02/07/2026 at 21:00, 10 hours 58 minutes ago Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 15 hours 22 minutes ago The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 15 hours 37 minutes ago NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 12 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 14 hours ago EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG
Published on 02/06/2026 at 18:22, 1 day 13 hours ago Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 13 hours ago Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 15 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 15 hours ago Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026
